相关临床试验
12
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
8.3%
已完成
2
16.7%
招募中
3
25.0%
终止
5
41.7%
Unknown
1
8.3%
暂无批准数据
- Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, creating a combined company focused on immunologically-driven disorders. - A concurrent $132 million private placement, co-led by Affinity Asset Advisors and Ikarian Capital, extends the cash runway through the second half of 2028. - The consolidated pipeline features KP-104 for PNH and renal disorders, briquilimab for SCID, and the preclinical KP-701 for autoantibody-mediated diseases. - Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront plus potential milestone payments.
- Jasper Therapeutics is developing antibody-based conditioning agents targeting CD117 (c-Kit) to replace traditional chemotherapy and radiation in stem cell transplant preparation. - The company's lead candidates are being evaluated in severe combined immunodeficiency and other hematologic or genetic conditions with high unmet need. - Jasper's platform strategy aims to position its conditioning technology as an enabling tool for gene and cell therapies developed by other companies through licensing and partnerships. - As a clinical-stage biotech without commercial products, the company relies on equity financing and collaborations to fund R&D, with shares trading on Nasdaq under ISIN US47191J1060.
- Jasper Therapeutics announced positive preliminary data from the ETESIAN Phase 1b study showing that a single 180mg dose of briquilimab significantly reduced airway hyperresponsiveness and sputum eosinophils in allergic asthma patients at both 6 and 12 weeks. - The study demonstrated improvements in lung function measures, with briquilimab showing 10.4% improvement in Late Asthmatic Response at 6 weeks and 8.7% at 12 weeks compared to baseline. - The company completed its internal investigation into anomalous BEACON study results, concluding that patient selection issues rather than drug product problems caused the unexpected lack of efficacy in US patients. - Briquilimab represents the first clinical study to evaluate an agent specifically targeting mast cells in asthma patients, potentially offering a new treatment option for underserved chronic asthma patients.
- RAGE Biotech, a Monash University spin-off, secured A$29 million in Series A funding led by IP Group Australia and Hostplus to advance RNA-based therapeutics for chronic inflammatory diseases. - The company's lead program RB042 is an inhaled splice-switching oligonucleotide therapy targeting chronic obstructive pulmonary disease and inflammatory lung conditions, preparing for first-in-human clinical trials. - RAGE Biotech appointed Dr Siro Perez as CEO and Dr Edwin Tucker as Chief Medical and Development Officer to lead the transition from pre-clinical research to clinical development. - The therapeutic approach targets the RAGE pathway, a critical driver of inflammatory responses, using splice-switching oligonucleotides to modify disease pathways at the genetic level.
- Briquilimab demonstrated remarkable efficacy in chronic spontaneous urticaria (CSU) with 89% of patients achieving complete response by week 2 in valid cohorts of the BEACON Phase 1b/2a trial. - Manufacturing defects in drug lot A349954 affected 10 of 13 patients in high-dose cohorts, resulting in minimal therapeutic response and delaying Phase 2b trials until mid-2026. - The anti-KIT monoclonal antibody offers potential advantages over current treatments with quarterly dosing versus Xolair's weekly or biweekly injections, targeting a $500M+ annual revenue opportunity in CSU. - Jasper has pivoted to focus solely on CSU development while halting asthma and SCID programs to preserve cash runway amid manufacturing challenges.
- Jasper Therapeutics will present four abstracts on briquilimab at the EAACI Congress 2025 in Glasgow, featuring initial clinical data from the SPOTLIGHT Phase 1b/2a study. - The company will showcase results from the 180mg cohort evaluating briquilimab in cold urticaria and symptomatic dermographism patients who remain symptomatic despite antihistamine treatment. - Briquilimab is a novel anti-c-Kit monoclonal antibody that depletes mast cells through apoptosis, targeting the underlying inflammatory source in chronic urticaria and asthma. - The presentations will include both clinical trial data and preclinical studies demonstrating briquilimab's efficacy in mast cell-driven diseases including chronic spontaneous urticaria.
• Tenvie Therapeutics, backed by Arch Venture Partners and others, debuts with $200 million to develop drugs targeting neurodegenerative diseases. • Sana Biotechnology's technology enables successful pancreatic islet cell transplant in a Type 1 diabetes patient without immunosuppression. • Jasper Therapeutics shares mixed Phase 1b/2a data on briquilimab for chronic spontaneous urticaria, leading to a stock decline. • Stoke Therapeutics finalizes plans for a Phase 3 trial of its experimental drug for Dravet syndrome, with data expected by 2027.
- Jasper Therapeutics reported positive preliminary data from its BEACON Phase 1b/2a study of briquilimab in adults with chronic spontaneous urticaria (CSU). - The study demonstrated rapid and durable symptom control, with substantial reductions in UAS7 scores across multiple dosing cohorts. - Complete responses (UAS7 = 0) were observed in 100% of patients in the 240mg single-dose cohort at 8 weeks. - Briquilimab was well-tolerated, supporting the commencement of a CSU registrational program expected in the second half of 2025.
• Jasper Therapeutics has dosed the first patient in its Phase 1b/2a ETESIAN clinical study, evaluating briquilimab in allergic asthma. • The ETESIAN study is a double-blind, placebo-controlled trial assessing a single subcutaneous dose of 180mg briquilimab in approximately 30 patients. • Briquilimab, a c-Kit inhibitor, aims to deplete mast cells in the airways, potentially offering a novel approach for asthma treatment. • Initial data from the ETESIAN study is anticipated in the second half of 2025, providing insights into briquilimab's efficacy and safety.
• Jasper Therapeutics is focused on advancing safer conditioning agents and stem cell engineering to improve hematopoietic stem cell transplants and gene therapies. • The company's lead compound, JSP191, is a conditioning antibody designed to clear hematopoietic stem cells from the bone marrow, reducing risks associated with current transplant regimens. • Jasper is also developing Briquilimab, targeting CD117, with promising results in preventing allergic conditions like anaphylaxis and allergic asthma in animal models. • Strategic partnerships and recent financial results underscore Jasper's commitment to innovation and expanding the availability of curative therapies.
